Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Aug 26:2024.08.23.609450.
doi: 10.1101/2024.08.23.609450.

TUMOR-INFILTRATING NOCICEPTOR NEURONS PROMOTE IMMUNOSUPPRESSION

Affiliations

TUMOR-INFILTRATING NOCICEPTOR NEURONS PROMOTE IMMUNOSUPPRESSION

Anthony C Restaino et al. bioRxiv. .

Update in

Abstract

Nociceptor neurons impact tumor immunity. Removing nociceptor neurons reduced myeloid-derived suppressor cell (MDSCs) tumor infiltration in mouse models of head and neck carcinoma and melanoma. Carcinoma-released small extracellular vesicles (sEVs) attract nociceptive nerves to tumors. sEV-deficient tumors fail to develop in mice lacking nociceptor neurons. Exposure of dorsal root ganglia (DRG) neurons to cancer sEVs elevated expression of Substance P, IL-6 and injury-related neuronal markers while treatment with cancer sEVs and cytotoxic CD8 T-cells induced an immunosuppressive state (increased exhaustion ligands and cytokines). Cancer patient sEVs enhanced DRG responses to capsaicin, indicating increased nociceptor sensitivity. Conditioned media from DRG and cancer cell co-cultures promoted expression of MDSC markers in primary bone marrow cells while DRG conditioned media together with cancer sEVs induced checkpoint expression on T-cells. Our findings indicate that nociceptor neurons facilitate CD8+ T cell exhaustion and enhance MDSC infiltration. Targeting nociceptor-released IL-6 emerges as a novel strategy to disrupt harmful neuro-immune interactions in cancer and enhance anti-tumor immunity.

PubMed Disclaimer

Conflict of interest statement

Sebastien Talbot is a minority stake holder in Nocion Therapeutics and received funding from Nocion Therapeutics and Cygnal Therapeutics. All other authors declare they have no competing interests.

References

    1. Longworth M. S., Laimins L. A., Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68, 362–372 (2004). - PMC - PubMed
    1. McIlwain W. R., Sood A. J., Nguyen S. A., Day T. A., Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg 140, 441–447 (2014). - PubMed
    1. Johnson D. E. et al. , Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6, 92 (2020). - PMC - PubMed
    1. Siegel R. L., Miller K. D., Jemal A., Cancer Statistics, 2017. CA Cancer J Clin 67, 7–30 (2017). - PubMed
    1. Cillo A. R. et al. , Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. Immunity 52, 183–199 e189 (2020). - PMC - PubMed

Publication types